Medpace (NASDAQ:MEDP) Price Target Lowered to $539.00 at Truist Financial

Medpace (NASDAQ:MEDP) had its target price decreased by analysts at Truist Financial from $555.00 to $539.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “hold” rating on the stock. Truist Financial’s price target points to a potential upside of 20.84% from the company’s current price.

Other analysts have also recently issued reports about the company. Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a research report on Wednesday, January 28th. BMO Capital Markets started coverage on shares of Medpace in a research note on Thursday, November 13th. They set a “market perform” rating and a $600.00 price objective on the stock. TD Cowen reiterated a “sell” rating on shares of Medpace in a research report on Friday, October 24th. Robert W. Baird raised shares of Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 target price on the stock in a research note on Tuesday. Finally, Barclays boosted their price target on shares of Medpace from $485.00 to $525.00 and gave the stock an “underweight” rating in a research report on Monday, December 15th. Three investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, Medpace has an average rating of “Hold” and an average price target of $499.45.

Medpace Trading Down 15.9%

NASDAQ:MEDP opened at $446.05 on Wednesday. The stock has a 50 day moving average of $575.55 and a 200-day moving average of $539.56. The firm has a market capitalization of $12.57 billion, a PE ratio of 29.15, a price-to-earnings-growth ratio of 1.78 and a beta of 1.42. Medpace has a 52 week low of $250.05 and a 52 week high of $628.92.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. Medpace had a return on equity of 127.72% and a net margin of 17.83%.The company had revenue of $708.45 million for the quarter, compared to analysts’ expectations of $689.53 million. During the same period last year, the business posted $3.67 earnings per share. The firm’s quarterly revenue was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, analysts predict that Medpace will post 12.29 EPS for the current fiscal year.

Insider Activity at Medpace

In other Medpace news, VP Susan E. Burwig sold 20,000 shares of the firm’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the transaction, the vice president directly owned 27,500 shares in the company, valued at $16,751,625. This trade represents a 42.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO August J. Troendle sold 668 shares of the firm’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $590.69, for a total value of $394,580.92. Following the completion of the transaction, the chief executive officer directly owned 646,184 shares in the company, valued at $381,694,426.96. The trade was a 0.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 296,880 shares of company stock valued at $178,815,404. Insiders own 20.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quent Capital LLC bought a new position in Medpace in the 3rd quarter worth approximately $25,000. Optiver Holding B.V. bought a new position in Medpace during the 3rd quarter worth about $27,000. Geneos Wealth Management Inc. lifted its position in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares in the last quarter. Steigerwald Gordon & Koch Inc. bought a new position in shares of Medpace in the 4th quarter valued at about $30,000. Finally, Elyxium Wealth LLC acquired a new position in Medpace during the fourth quarter worth $30,000. Institutional investors own 77.98% of the company’s stock.

Medpace News Summary

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Q4 beat on revenue and EPS — Medpace reported $708.5M revenue and $4.67 EPS, topping expectations and showing 32% YoY revenue growth; the strong quarter underpins organic demand for CRO services. Medpace Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Raised FY2026 guidance — Medpace set EPS guidance of $16.68–$17.50 and revenue guidance of $2.8B–$2.9B, above consensus, signaling management expects continued top-line growth despite some near-term headwinds. Medpace FY2026 Guidance
• Positive Sentiment: New CRO win — Zelluna selected Medpace as CRO for its ZIMA-101 first-in-human trial, adding client work that supports future service revenue. Zelluna selects Medpace as CRO
• Positive Sentiment: Analyst upgrade — Robert W. Baird upgraded MEDP to Outperform with a $564 PT, signaling increased analyst conviction and potential catalyst for buying interest. Baird upgrades Medpace
• Neutral Sentiment: Investor materials and call transparency — Earnings call transcript and slide deck are available for details on bookings, backlog and margin drivers; useful for modeling but not immediate catalysts. Earnings call transcript
• Negative Sentiment: Backlog normalization and trial timing drove the selloff — Despite the beat, investors reacted to management commentary about backlog growth slowing and timing shifts in metabolic trials, which compress near-term revenue visibility and prompted a roughly 5% intraday drop. Medpace shares tumble despite Q4 beat

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.